According to the statement, tobacco-related cancer is estimated to contribute 370,000 cases which is 27.1 per cent of the total cancer burden in 2020
Researchers have developed a new nano-drug candidate that kills triple negative breast cancer cells, which is one of the most aggressive and fatal types of breast cancer
According to a report released by ICMR in 2018, cancer took more than 700,000 lives in India
On World Cancer Day, Business Standard looks at some start-ups which are redefining cancer diagnosis, screening and care with novel ideas and niche technologies
Radiologists miss about 20 per cent of breast cancers in mammograms, the American Cancer Society says, and half of all women who get the screenings over a 10-year period have a false positive result
The trastuzumab drug has shown "high efficacy" in curing early stage breast cancer and in some cases more advanced forms of the disease
This includes keeping your weight in check, being physically active, eating fruits and vegetables, avoid alcohol and cigarettes, etc
Breast cancer originates in the breast tissue when cells start growing abnormally and stop functioning like normal cells
The blood test identifies the body's immune response to substances produced by tumour cells
Periods of exercise in the studies ranged from 30 to 80 minutes and were performed on one to five days a week for up to 12 weeks
These findings, published in the journal BMJ, identify a need for future research
Targeting this switch with a different drug could help reverse this resistance
Niramai has developed an artificial intelligence-based solution for detecting early-stage breast cancer.
Breast cancer's shockingly high fatality rate in India is due in large part to the fact that it is mostly detected at later stages
Breast cancer survivors also had up to twice the risk of depression
Digital mammogram with tomosynthesis is a superb tool to detect even very small cancer
Zydus Cadila has more than 220 approvals and so far
The study included participants who had a normal BMI (between 18.5 to 25.0) and no history of breast cancer
Biocon said biosimilar trastuzumab will be manufactured by it and supplied to Libbs for commercialisation in Brazil
A recent study showed that these women seek medical care extremely late